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M. tuberculosis thymidine monophosphate kinase (mtTMPK; EC 2.7.4.9), a member of the large superfamily of nucleoside monophosphate kinases, catalyzes the reversible phosphorylation of deoxythymidine 5′-monophosphate (dTMP) to deoxythymidine 5′-diphosphate in the presence of Mg 2+ and ATP. This catalysis step plays a crucial role in both the de novo and salvage pathways of DNA synthesis for mycobacterial growth. [18, 19] Significant progress has been made in the development of mtTMPK inhibitors using several in silico drug screening methods (e.g., docking studies, pharmacophore models, and quantitative structureactivity relationship methods). [20] [21] [22] [23] In fact, several research groups have reported on the successful design and synthesis of nucleotide analog mtTMPK inhibitors (i.e., α-thymidine, acyclic nucleoside, and bicyclic nucleoside derivatives). [24] [25] [26] Therefore, mtTMPK is considered to be an attractive target for the development of effective antibiotics against TB. In this study, we performed pharmacophore-based in silico screening, targeting mtTMPK with a compound library of 461,383 chemicals, which yielded one hit (KTP3) that was able to inhibit the growth of Mycobacterium smegmatis. Subsequently, we rescreened compounds similar to KTP3 and obtained potentially active compounds from a web-based database. We identified two KTP3 analogs (KTPS1 and KTPS2) that showed antibacterial effects against M. smegmatis. Moreover, the most potent compound, KTPS1, did not exhibit any significant toxic effects on model intestinal bacteria or several mammalian cells.
In addition, we experimentally demonstrated that two chemical compounds (KTPS1 and KTPS2) directly inhibited mtTMPK enzymatic activity to some extent, suggesting that these compounds have off-target activities against Mycobacterium. We anticipate that structural and experimental information on these active chemicals will contribute to the development of anti-TB medical drugs.
MaterIals and Methods

Chemical compound library
For the pharmacophore-based in silico screening, we generated a virtual chemical compound library (ChemBridge; 461,383 chemicals) using the wash and energy minimize modules of Molecular Operating Environment (MOE) version 2011.10. [27] First, the two-dimensional structures were converted into three-dimensional structures. After generating the three-dimensional structures, the protonation state was treated using the partial charge module in MOE. The multiconformation structural data of the compounds were generated using the LowMode MD module [28] in MOE with default parameters. [29] [30] [31] 
Pharmacophore-based in silico screening
The crystal data for mtTMPK (PDB ID: 1MRN) [32] were obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank. [33] Before using the mtTMPK crystal structure in the in silico drug screening, we removed all water molecule atoms and the P 1 -(adenosine-5′)-P 5 -(thymidine-5′)-pentaphosphate (Ap 5 T) atoms of the inhibitor from the original crystal structure data. In addition, hydrogen atoms were added to mtTMPK using the Protonate 3D module in MOE 2011.10 at pH 7.0 with the MMFF94x force field. The energy was minimized using the energy minimize module of MOE 2011.10. [27] As part of this process, all of the heavy atoms, except the hydrogen atoms, were tethered to relieve any short contacts.
The pharmacophore-based in silico screening was performed using MOE 2011.10 [27] and CCDC GOLD suite version 5.3. [34] The first pharmacophore-based screening was performed using the pharmacophore search module in MOE 2011.10 with default parameters. [27] The candidate compounds obtained from the first screening were then docked into the active site cleft of mtTMPK, and putative protein-chemical compound binding affinities were predicted using the GOLD program, which uses a genetic algorithm to search for flexible ligand conformations and allows for partial receptor flexibility. [34] The docking simulations were performed with the default settings in GOLD (operations = 100,000, island = 5, migration = 15, mutation = 95, and crossover = 95). [29] [30] [31] The pharmacophore-based in silico screening results were analyzed using the protein-ligand interaction fingerprint and ligand interaction modules in MOE 2011.10. [27] 
Screening of similar chemical compounds
A total of 13 compounds similar to the initial active compound KTP3 were chosen from the Hit2Lead web-based database after two-and three-dimensional similarity searches. [35] The docking studies were performed with a GOLD screening using the multiconformation structural data of the 13 analog compounds.
Docking metric
We generated a decoy set of chemical compounds of mtTMPK based on the active ligands of mtTMPK (K i values = 7.2-116 µM) [24, 25] using the directory of useful decoys enhanced test set generator. [36] Three-dimensional structures of the ligand and decoy set chemical compounds were generated using the energy minimize and LowMode MD modules in MOE 2011.10. The docking studies were performed using the same methods and parameters as the single-and multi-conformational GOLD docking processes. The receiver operating characteristic (ROC) curve and area under the curve (AUC) values were calculated using Epi package in R version 3.0.2 (Gentofte, Denmark).
Sequence alignment and homology modeling
The amino acid sequence of mtTMPK (accession number: WP_003904223) retrieved from the Basic Local Alignment Search Tool (BLAST) database [37] was aligned with that of msTMPK (accession number: WP_011727970) using MOE 2011.10. [27] The three-dimensional structure of msTMPK was generated using the homology modeling module in MOE 2011.10 with default parameters. [31] 
Chemical compounds
All chemical compounds (KTP1-KTP5 and KTPS1-KTPS4) were purchased from ChemBridge Corporation [35] and dissolved in dimethyl sulfoxide (DMSO) (Sigma) for the in vitro assays. The chemical compounds (supplier IDs are given in parentheses) used include the following: The nuclear magnetic resonance or liquid chromatography-mass spectrometry data related to these compounds are available on the ChemBridge Corporation's website at http://www. chembridge.com.
Bacterial strains and bacterial growth assays
The model bacterial strain M. smegmatis was obtained from the RIKEN BioResource Center (Saitama, Japan). [38] The Escherichia coli JM109 and BL21 strains were kindly provided by Dr. S. Sueda (Kyushu Institute of Technology).
The bacterial growth assays were performed using previously described methods with slight modifications. [29, 30] Briefly, M. smegmatis and E. coli were incubated for 24 h and overnight, respectively, at 250 rpm and 37°C in 4 mL of the corresponding culture medium (M. smegmatis: 3.7% brain-heart infusion broth [Fluka]; E. coli: 0.5% yeast extract [BD], 1% tryptone [BD], and 0.5% NaCl [Wako], titrated to pH 7.4 using NaOH [Sigma]). We used ×8 dilutions of the M. smegmatis culture and ×10 dilutions of the E. coli culture for the growth assays. The bacterial strains were seeded in 96-well assay plates (Nunc) with a 100-µL total volume and incubated in culture media containing the specified compounds. As a positive control, isoniazid (INH) (LKT) and triclosan (TCS; TCI) were used for M. smegmatis and E. coli growth assays (at 250 rpm and 37°C), respectively. As a negative control, 0.3% DMSO (Sigma) was used in each bacterial assay. After 4, 8, and 24 h, we measured the absorbance (at 595 nm) of the culture medium using a microplate reader (Bio-Rad Model 680).
Lactate dehydrogenase leakage assay
The lactate dehydrogenase (LDH) leakage from the cytosol of damaged cells (K562 cells) was measured using a Cytotoxicity Detection Kit PLUS (LDH) (Roche), with a slight modification of the manufacturer's protocol. For this assay, the culture medium was replaced with fresh medium (1% fetal bovine serum) containing one of the compounds or TCS (50 µM) as a positive control, and the cells were seeded in 96-well assay pates (Corning) with a 100 µL total volume at 5.0 × 10 3 cells/ well and subsequently incubated for 1 day. We added 5 µL/ well of lysis solution to the high control and incubated it for 15 min at 37°C in 5% CO 2 . Next, we added 100 µL/well of the reaction mixture into each well and incubated the plate for 7 min at room temperature (to protect it from the light). After 7 min, we added 50 µL/well of the stop solution into each well. The absorbance measurements were performed at 490 nm using a microplate reader (Bio-Rad Model 680).
Enzymatic assay
The enzymatic activity of mtTMPK was assayed using previously described methods. [19] Purified recombinant mtTMPK was used in the enzymatic assay. [18] The enzymatic reactions were performed at 30°C and with a final volume of 500 µL containing 50 mM Tris-HCl buffer (pH 7.4), 50 mM KCl, 200 µM NADH, 1 mM phosphoenol pyruvate, and 2 units each of LDH, pyruvate kinase, and nucleoside diphosphate kinase. The concentrations of dTMP and ATP were kept constant at 50 µM and 500 µM, respectively. The oxidation of NADH (at 340 nm) was measured with an Eppendorf ECOM 6122 photometer.
Statistical analysis
All statistical analyses were performed using R version 3.0.2 (The R Foundation for Statistical Computing, Vienna, Austria) and GraphPad Prism version 4 (GraphPad Software, Inc. (San Diego, CA)). Figure S6 ]; the inhibitory effects of the active compounds (KTP3, KTPS1, and KTPS2) on the enzymatic activity of mtTMPK [Table S1 ]; and the physicochemical properties of the active compounds [Table S2 ]. These materials are available free of charge through the Internet at http://www. sciencedirect.com.
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Pharmacophore-based in silico screening
We performed a three-step pharmacophore-based in silico screening using the pharmacophore search module in MOE and docking simulations with the GOLD program to identify active compounds against mtTMPK [ Figure 1 ]. The dTMP binding site comprises the following amino acid residues: Asp 9, Tyr 39, Phe 70, Arg 74, Arg 95, Asn 100, Tyr 103, Arg 153, and Glu 166 [ Figure 2 ]. [32, 39] First, the constructed structural library of 461,383 chemical compounds was screened using the pharmacophore search module in MOE, [9, 27] and 2645 hit compounds were identified. After the pharmacophore screening, we performed a GOLD screening using a single conformation per compound (AUC values of the ROC analysis = 0.713; Figure S1a ) and identified the top 500 compounds with GOLD scores greater than 75. Subsequently, we performed a second GOLD screening using five conformations per compound (AUC values of the ROC analysis = 0.733; Figure S1b ). After the second GOLD screening, the top 239 ranked compounds showed average GOLD scores >80. We then eliminated compounds based on the following criteria: (1) The compound was evaluated through past high-throughput screening (HTS) using the PubChem database [40] and (2) the compound has no direct interactions (i.e. vdW and/ or hydrogen bonds) with the dTMP binding site. Finally, we selected five chemical compounds (KTP1-KTP5) with average GOLD scores >80 (80.92-94.11). The binding potencies of these five compounds to the homology-modeled M. smegmatis TMPK (msTMPK) were verified by GOLD simulations. The GOLD scores of these compounds (KTP1-KTP5) ranged from 80.4 to 100.17 [ Table 1 ].
In vitro antimycobacterial assay of the candidate compounds KTP1-KTP5
We performed an antimycobacterial assay to confirm that the five candidate compounds (KTP1-KTP5) actually exhibited inhibitory effects on the growth of the model mycobacteria M. smegmatis (biosafety level 1). A BLAST analysis [37] showed that the amino acid sequence of mtTMPK was similar to that of msTMPK (identity rate = 66%, positive rate = 72%). All amino acid residues in the active site of msTMPK are completely conserved in mtTMPK [ Figure S2 ]. One of the five compounds, KTP3 (100 µM), significantly inhibited the growth of M. smegmatis after 24 h compared with the negative control (DMSO). In contrast, KTP1, KTP2, KTP4, and KTP5 had no significant or weak inhibitory effects on M. smegmatis growth when compared with the negative and positive controls [ Figure 3 ]. Notably, KTP3 showed inhibitory effects on the growth of M. smegmatis similar to those of INH.
Screening of KTP3 analogs based on chemical structure similarity
We rescreened the KTP3 analogs expected to have higher efficacy than KTP3. We obtained 13 KTP3 analogs from a web-based database (Hit2Lead). [35] Subsequently, we performed GOLD docking simulations targeting mtTMPK with multiconformations of the 13 KTP3 analogs. As a result, we identified four structurally similar compounds (KTPS1-KTPS4) with average GOLD scores >70. In addition, the GOLD scores of KTPS1-KTPS4 were calculated from the msTMPK simulations, which showed similar values (75.04-95.82) to the calculated values from the mtTMPK simulations (74.70-97.03). The compounds KTP3 and KTPS1-KTPS4 have a tetrahydro-2-furanyl ring as a common scaffold [ Table 2 ]. 
In vitro antimycobacterial assay of the KTP3 analogs
We examined whether the four KTP3 analogs (KTPS1-KTPS4) truly exhibited an inhibitory effect on the growth of M. smegmatis. Compounds KTPS1 and KTPS2 (100 µM) exhibited significant inhibitory effects (more than 50%) on the growth of M. smegmatis after 24 h, whereas KTPS3 and KTPS4 had weak inhibitory effects on the growth of M. smegmatis [ Figure S3 ].
Determination of the half-maximal inhibitory concentration and minimum inhibitory concentration 50% values of the active compounds
We investigated the dose-dependent effects of the active compounds (KTP3, KTPS1, and KTPS2) on the growth of M. smegmatis. The experimentally determined half-maximal inhibitory concentration (IC 50 ) values of KTP3, KTPS1, and KTPS2 for M. smegmatis were 23.9, 8.04, and 17.1 µM, respectively [ Figure 4 ]. It should be noted that the IC 50 value of KTPS1 is at the same level as that of INH (experimentally determined IC 50 = 10.3 µM; Figure S4 ). Furthermore, we determined the minimum inhibitory concentration 50% (MIC 50 ) values of INH, KTP3, and KTPS1 for M. smegmatis [ Table 3 ]. We did not determine the MIC 50 value of the active compound KTPS2 because KTPS2 did not completely inhibit the growth of M. smegmatis at 100 µM [ Figure S3 ].
Enterobacterial and mammalian cell toxicity assays of the active compounds
We performed enterobacterial toxicity assays using E. coli as the model bacteria. For the treatment of TB, it is necessary for patients to take the first-line anti-TB drugs for a long period (at least 6 months). [7, 9] Drugs with enterobacterial toxicity are not suitable for TB treatment. Therefore, we assessed the enterobacterial toxicity of the compounds KTP3, KTPS1, and KTPS2 against the JM109 and BL21 E. coli strains. None of the compounds had any toxic effects on the growth of either strain after 8 h [ Figure S5 ]. Furthermore, we assessed the cytotoxicity of the KTP3, KTPS1, and KTPS2 compounds against cultured mammalian cells (Madin-Darby canine kidney cells: MDCK, human neuroblastoma cells: SH-SY5Y, human acute monocyclic leukemia cells: THP-1, human promyelocytic leukemia cells: HL-60, and human acute myelocytic leukemia cells: K562). KTPS1 did not show any significant toxic effects on cultured MDCK, SH-SY5Y, THP-1, HL-60, and K562 cells, whereas KTP3 and KTPS2 showed significant toxic effects on these mammalian cells [ Figures 5 and S6 ]. 
Mycobacterium tuberculosis thymidine monophosphate kinase enzymatic assays
Enzymatic assays were performed to assess whether the three active chemical compounds (KTP3, KTPS1, and KTPS2) directly inhibit the enzymatic activity of mtTMPK. Two of the three compounds, KTPS1 (100 µM) and KTPS2 (116 µM), inhibited mtTMPK activity by 18% and 36%, respectively, compared with the negative control, DMSO (0.3%). Compound KTP3 had no significant inhibitory effects on mtTMPK activity at 20 µM [ Table S1 ]. It is noteworthy that these compounds formed precipitate at concentrations higher than 100 µM (approximately 20 µM for KTP3) when the compounds were added to the enzymatic reaction buffer. Therefore, we could not complete our analysis of the effects of these compounds on mtTMPK activity (e.g., dose-dependent effects). completely inhibited the growth of M. smegmatis, inhibitory effects on mtTMPK activity were not observed at a concentration of 20 µM. In contrast, the compounds KTP1 (cLogP = 6.16), KTP2 (cLogP = 4.27), KTP4 (cLogP = 4.10), and KTP5 (cLogP = 4.06) had no significant or weak inhibitory effects on M. smegmatis growth although these compounds had higher cLogP values compared with KTP3. It could be hypothesized that these compounds may modulate several biological targets, and these off-target activities may be essential for effectiveness. Indeed, previous research has suggested that effective drugs bind to multiple proteins (although the drugs are designed to be highly selective), and this polypharmacology may be essential for efficacy. [41] [42] [43] For example, d-cycloserine, associated with the second-line drugs for TB, inhibits mycobacterial cell wall biosynthesis through the inhibition of both d-alanine ligase and d-alanine racemase. [44] Combined with weak enzymatic inhibition, these results may suggest that the antibacterial activity was driven by polypharmacology rather than lipophilicity. Thus, the biological assay data for KTP3, KTPS1, and KTPS2 and the prediction of possible off-target activities with a computational approach (i.e., network analysis) are likely to be useful for the development of novel anti-TB drugs.
In general, unique physicochemical properties are required for antimycobacterial agents because of the distinctive architecture of mycobacterial cell walls (containing mycolic acids), which affect membrane and cell wall permeability. [45, 46] Previously, Trias and Benz [47] reported that M. smegmatis is approximately 20 times less permeable than E. coli. In addition, O'Shea and Moser [45] reported that the physicochemical property values of chemical compounds with only Gram-positive activity (lipophilicity, molecular weight [MW], and polar surface area [PSA] values) were higher than those of chemical compounds with Gram-negative activity. Thus, taking physicochemical properties into account, LogP, MW, and topological PSA (tPSA) values are key factors that affect the efficacy of drugs. The physicochemical properties of each of the active compounds are shown in Table S2 . The most active compound, KTPS1, had a higher lipophilicity (cLogP = 3.86) and higher MW and tPSA values (MW = 632, tPSA = 137.38) than KTP3. Therefore, compound KTPS1 is physically preferred over the other active compounds.
Of the nine compounds examined in the present study, three potential antimycobacterial compounds were identified through pharmacophore-based in silico screening, which resulted in a 33% hit rate. In contrast, the hit rate of HTS methods targeting Mycobacterium was approximately 1%-5%. [48, 49] Therefore, our screening methods are expected to be effective for the identification of novel compound hits against not only TB but also other diseases.
conclusIon
We have identified three active compounds (KTP3, KTPS1, and KTPS2) against the model mycobacterial strain M. smegmatis using pharmacophore-based in silico screening. KTPS1 showed no inhibition of the growth of the JM109 and BL21 E. coli strains and had no observable cytotoxic effects on several mammalian cells (MDCK, SH-SY5Y, THP-1, HL-60, and K562 cells). We expect that the structural information generated by the present study will be helpful for the development of anti-TB chemical compounds with improved potency.
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